{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T17:42:05Z","timestamp":1788975725070,"version":"build-2803163510"},"reference-count":27,"publisher":"Wiley","issue":"9","license":[{"start":{"date-parts":[[2025,8,6]],"date-time":"2025-08-06T00:00:00Z","timestamp":1754438400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Journal of Viral Hepatitis"],"published-print":{"date-parts":[[2025,9]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>\n                    The objective of this study is to analyse the prevalence and clinical characteristics of HCV\/HBV coinfection in Guizhou, and evaluate the rate of HBV reactivation during and after anti\u2010HCV treatment in a real\u2010world study. This retrospective study included 1652 patients with hepatitis C virus (HCV) infection who received direct\u2010acting antiviral (DAA) therapy at the Guiyang Public Health Clinical Center between January 2018 and December 2022 Baseline, on\u2010treatment and posttreatment data were collected, including HCV RNA, HCV genotypes, liver function, hepatitis B virus (HBV) markers (HBsAg, HBcAb) and HBV DNA levels. The HCV\/HBV coinfection rate was analysed, and the risk of HBV reactivation and disease progression following DAA therapy was assessed. Among the 1652 HCV\u2010infected patients, the HCV\/HBV coinfection rate was 49.88% (824\/1652). Of these, 5.08% (84\/1652) were HBsAg\u2010positive, while 44.79% (740\/1652) were HBsAg\u2010negative\/HBcAb\u2010positive with HBV DNA\u2009&lt;\u200920\u2009IU\/mL. Compared to patients with HCV monoinfection, HBsAg\u2010positive patients had a higher proportion of males, compensated and decompensated cirrhosis, hepatocellular carcinoma (HCC) and lower platelet (PLT) counts (\n                    <jats:italic>\u03c7<\/jats:italic>\n                    <jats:sup>2<\/jats:sup>\n                    \u2009=\u200915.482, 46.101;\n                    <jats:italic>F<\/jats:italic>\n                    \u2009=\u20097.292; all\n                    <jats:italic>p<\/jats:italic>\n                    \u2009&lt;\u20090.05). Differences in HCV genotype distribution were observed among various HBV immune status groups (\n                    <jats:italic>\u03c7<\/jats:italic>\n                    <jats:sup>2<\/jats:sup>\n                    \u2009=\u200932.529,\n                    <jats:italic>p<\/jats:italic>\n                    \u2009&lt;\u20090.05). The cumulative incidence of HBV reactivation in HCV\/HBV coinfected patients treated with DAAs was 1.2% (10\/824). Among these, the reactivation rate was 16.67% (9\/54) in HBsAg\u2010positive patients without prophylactic anti\u2010HBV therapy and 0.1% (1\/740) in HBsAg\u2010negative\/HBcAb\u2010positive patients. Baseline HBsAg levels were significantly higher in patients with HBV reactivation than in those without reactivation (\n                    <jats:italic>Z<\/jats:italic>\n                    \u2009=\u2009\u22124.291,\n                    <jats:italic>p<\/jats:italic>\n                    \u2009&lt;\u20090.05). No significant changes were observed in liver function or PLT levels after HBV reactivation compared to baseline (\n                    <jats:italic>p<\/jats:italic>\n                    \u2009&gt;\u20090.05), and no cases of liver failure were reported. In Guizhou, a relatively high prevalence of HBsAg\u2010positivity and a large proportion of past HBV exposure (HBsAg\u2010negative\/HBcAb\u2010positive, HBV DNA &lt;\u200920\u2009IU\/mL) were observed among HCV\u2010infected patients. While HBV reactivation can occur in HCV\/HBV coinfected patients undergoing DAA therapy, the overall risk is low. A baseline HBsAg level &gt;\u2009185\u2009IU\/mL is a significant risk factor for HBV reactivation.\n                  <\/jats:p>","DOI":"10.1111\/jvh.70061","type":"journal-article","created":{"date-parts":[[2025,8,6]],"date-time":"2025-08-06T13:18:51Z","timestamp":1754486331000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Clinical Observational Study on\n                    <scp>HBV<\/scp>\n                    Reactivation After Direct\u2010Acting Antiviral Therapy in\n                    <scp>HCV<\/scp>\n                    \/\n                    <scp>HBV<\/scp>\n                    Coinfected Patients in Guizhou, China"],"prefix":"10.1111","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-6018-1443","authenticated-orcid":false,"given":"Mei","family":"Wang","sequence":"first","affiliation":[{"name":"Department of Hepatology Guiyang Public Health Clinical Center  Guiyang China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Wang","sequence":"additional","affiliation":[{"name":"Laboratory Department Guiyang Public Health Clinical Center  Guiyang China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhigang","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Hepatology Guiyang Public Health Clinical Center  Guiyang China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Changming","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Hepatology Guiyang Public Health Clinical Center  Guiyang China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Hepatology Guiyang Public Health Clinical Center  Guiyang China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huagang","family":"Xiong","sequence":"additional","affiliation":[{"name":"Department of Hepatology Guiyang Public Health Clinical Center  Guiyang China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2025,8,6]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M204241200"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1006\/viro.2002.1701"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2007.05.052"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.7326\/M17-0377"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2017.03.021"},{"issue":"6","key":"e_1_2_8_7_1","first-page":"1425","article-title":"Guidelines for the Prevention and Treatment of Chronic Hepatitis B (Version 2022)","volume":"11","author":"Chinese Society of Hepatology, Chinese Medical Association","year":"2023","journal-title":"Journal of Clinical and Translational Hepatology"},{"issue":"1","key":"e_1_2_8_8_1","first-page":"29","article-title":"Guidelines for the Prevention and Treatment of Hepatitis C (2022 Version)","volume":"41","author":"Chinese Society of Hepatology and Chinese Society of Infectious Diseases, Chinese Medical Association","year":"2023","journal-title":"Chinese Journal of Infectious Diseases"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12072-021-10239-x"},{"issue":"2","key":"e_1_2_8_10_1","first-page":"309","article-title":"Distribution Characteristics of Hepatitis C Virus Genotypes in Guizhou, China","volume":"35","author":"Wang M.","year":"2020","journal-title":"Journal of Clinical Hepatology"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11938-019-00236-3"},{"key":"e_1_2_8_12_1","unstructured":"World Health Organization \u201cGlobal Progress Report on HIV Viral Hepatitis and Sexually Transmitted Infections 2021: Accountability for the Global Health Sector Strategies 2016\u20132021: Actions for Impact \u201d(2021)."},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(03)00470-7"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/163.2.400"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2016-012016"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/civ859"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1080\/14787210.2020.1782189"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(98)80198-0"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.36.2335"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1665-2681(19)30803-8"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12072-011-9279-6"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/civ344"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jceh.2022.04.020"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2020.01.027"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2016.06.023"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciab971"},{"key":"e_1_2_8_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2021.11.032"},{"key":"e_1_2_8_28_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.29800"}],"container-title":["Journal of Viral Hepatitis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jvh.70061","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,29]],"date-time":"2025-11-29T05:00:41Z","timestamp":1764392441000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/jvh.70061"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,6]]},"references-count":27,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["10.1111\/jvh.70061"],"URL":"https:\/\/doi.org\/10.1111\/jvh.70061","archive":["Portico"],"relation":{},"ISSN":["1352-0504","1365-2893"],"issn-type":[{"value":"1352-0504","type":"print"},{"value":"1365-2893","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,6]]},"assertion":[{"value":"2024-12-20","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-07-22","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-08-06","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70061"}}